ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2858

Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases

Niels Eijkelkamp1, Sarita Hartgring2, Cristine Steen-Louws3, Hanneke Willemen4, Qiu-Ling Mao-Ying5, Cobi Heijnen5, Erik Hack6, Annemiek Kavelaars5 and J.A.G. van Roon7, 1Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands, 2Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3UMC Utrecht, Utrecht, Netherlands, 4NIDOD, UMC Utrecht, Utrecht, Netherlands, 5MD Anderson Cancer Center, Houston, TX, 6Immunology, UMC Utrecht, Utrecht, Netherlands, 7Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: analgesics, cytokines, Immune regulation, interleukins (IL) and pain management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial cell-mediated inflammatory responses in the spinal cord leading to enhanced pain perception (hyperalgesia), which is difficult to treat. Moreover, therapeutic options are limited. Despite the potential of IL4 and IL10 to inhibit inflammation and pain in experimental models, clinical studies were disappointing, likely due to poor bioavailability. We developed a novel option to inhibit multiple inflammatory responses by constructing an IL4/IL10 fusion protein (IL4-10 synerkine). This synerkine is a novel biologic that combines the distinct characteristics of IL4 and IL10, with an increased mass and anticipated improved bioavailability. Strong anti-inflammatory potential of the synerkine was demonstrated in human in vitro assays. Our objective was to investigate the capacity of IL4-10 synerkine to treat chronic pain induced by inflammation or nerve damage.

Methods: IL4-10 synerkine, injected intrathecally (it), was tested in 3 mouse models of chronic pain. First, chronic inflammatory hyperalgesia was induced by intraplantar injection of carrageenan. Secondly, we used mice with a cell-specific reduction of ~50% in GRK2 level in microglia/macrophages (LysM-GRK2+/- mice) that develop persistent inflammatory hyperalgesia after a single intraplantar injection of IL-1b, while WT mice develop a transient hyperalgesia. Thirdly, chronic neuropathic pain was induced by spared nerve injury (SNI). Hyperalgesia was assessed by Hargreaves test to determine heat withdrawal latencies and Von Frey hairs to determine mechanical thresholds. To demonstrate surplus value of the synerkine, IL-4 and IL-10 mono and combination therapies were tested.

Results: Intraplantar injection of carrageen induced profound persistent hyperalgesia in WT mice. A single it. injection of IL4-10 synerkine completely inhibited established carrageenan-induced persistent hyperalgesia (for 40, 100 and 200 ng all p<0.001) for at least 2 days. The highest dose of IL4-10 synerkine significantly inhibited hyperalgesia for 4 days (p<0.05). Injection of IL4, IL10, or a combination (100 ng) only modestly inhibited hyperalgesia (30-40%) for 1 day. It. administration of IL4-10 synerkine also dose-dependently inhibited IL-1β-induced persistent hyperalgesia in LYSM-GRK2+/- mice. Single injections of 100 ng and higher, completely prevented the development of IL-1β-induced hyperalgesia in LYSM-GRK2+/- mice (p<0.001). Moreover, it shortened the duration of transient IL-1β-induced hyperalgesia in WT mice. Interestingly, IL4-10 synerkine also inhibited mechanical hypersensitivity in the SNI neuropathic pain model, although for shorter time periods (6 hours).

Conclusion: IL4-10 synerkine, next to its strong anti-inflammatory properties, also robustly relieves hyperalgesia in models for inflammatory and neuropathic pain, superior to IL4 or IL10 mono or combination therapy. These data underscore the potential of IL4-10 synerkine to inhibit immunopathology and pain in inflammatory and degenerative rheumatic diseases.

 


Disclosure:

N. Eijkelkamp,
None;

S. Hartgring,
None;

C. Steen-Louws,
None;

H. Willemen,
None;

Q. L. Mao-Ying,
None;

C. Heijnen,
None;

E. Hack,
None;

A. Kavelaars,
None;

J. A. G. van Roon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-chronic-pain-by-il4-10-synerkine-is-superior-to-il-4-or-il-10-monotherapy-a-novel-strategy-to-restrain-pain-in-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology